Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 87.5% in September

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 100,300 shares, an increase of 87.5% from the August 31st total of 53,500 shares. Based on an average trading volume of 134,500 shares, the days-to-cover ratio is currently 0.7 days. Based on an average trading volume of 134,500 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

A number of brokerages have recently commented on ALPMY. Sanford C. Bernstein cut Astellas Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 2nd. Zacks Research raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Astellas Pharma presently has a consensus rating of “Buy”.

Astellas Pharma Stock Down 1.1%

Shares of ALPMY stock opened at $11.02 on Friday. The stock has a 50-day moving average of $11.09 and a 200-day moving average of $10.11. Astellas Pharma has a one year low of $8.37 and a one year high of $12.45. The company has a quick ratio of 0.89, a current ratio of 1.17 and a debt-to-equity ratio of 0.38.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Wednesday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.26. Astellas Pharma had a return on equity of 19.67% and a net margin of 4.34%.The business had revenue of $3.41 billion during the quarter, compared to analysts’ expectations of $3.20 billion. Analysts anticipate that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.